 The novel antipsychotics have had a huge impact upon the treatment of schizophrenia. The major advantage of these agents over their predecessors is their reduced risk of inducing EPS and probably TD. However, high acquisition costs have limited their availability worldwide and many patients will continue to be exposed to conventional antipsychotics for the foreseeable future. Development of an effective and affordable treatment for TD would therefore be of great benefit. 